Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Nurix Therapeutics announced a strategic partnership with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell blood cancers. Nurix will receive $700 million upfront with potential milestone payments up to $2.3 billion total. The companies will share development costs (40/60 split) and equally split U.S. commercialization profits, while Roche handles international sales with royalties to Nurix. NRIX stock surged 51.23% in premarket trading.

06/08/2026, 9:26 AM • Benzinga

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

05/13/2026, 7:00 AM • GlobeNewswire

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

Nurix Therapeutics presented preclinical data at AACR 2026 demonstrating advances across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972. The data showcase the potential of targeted protein degradation therapies to overcome limitations of traditional inhibitors, with NRX-0305 showing 142% lifespan extension in resistant melanoma models and NRX-4972 achieving 60% survival in SCLC models compared to 0% for existing AURKA inhibitors.

04/22/2026, 7:00 AM • GlobeNewswire

Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight

The follicular lymphoma drug development pipeline is experiencing significant growth with 45+ companies actively developing 50+ pipeline therapies. Major pharmaceutical players including AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and others are advancing promising candidates through various clinical trial phases, with approximately 5+ drugs in late-stage development. The emerging therapeutic landscape shows a shift toward targeted, oral, and patient-centric therapies with diverse mechanisms of action including protein degraders, kinase inhibitors, and immune-mediated approaches.

04/21/2026, 1:00 PM • GlobeNewswire

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.

04/08/2026, 6:00 AM • GlobeNewswire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Redmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.

02/22/2026, 1:12 PM • The Motley Fool

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

01/14/2026, 10:52 AM • Benzinga

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Nurix Therapeutics reported promising Phase 1 trial results for bexobrutideg, an investigational drug for relapsed or refractory chronic lymphocytic leukemia, showing an 83% objective response rate and a median progression-free survival of 22.1 months.

12/06/2025, 9:30 AM • GlobeNewswire

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.

12/01/2025, 7:00 AM • GlobeNewswire

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.

11/03/2025, 9:00 AM • GlobeNewswire

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Nurix Therapeutics raised $250 million through a stock offering to fund clinical development of drug candidates targeting chronic lymphocytic leukemia and potential autoimmune indications.

10/27/2025, 7:00 AM • GlobeNewswire

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics launched a pivotal Phase 2 clinical trial (DAYBreak) for bexobrutideg, a potential BTK degrader treatment for relapsed or refractory chronic lymphocytic leukemia, with plans for a Phase 3 confirmatory study in 2026.

10/22/2025, 6:00 AM • GlobeNewswire

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Nurix Therapeutics presented Phase 1a clinical data for NX-1607, a first-in-class oral CBL-B inhibitor, showing promising anti-tumor activity across multiple solid tumor types with evidence of immune activation and clinical benefits.

10/18/2025, 3:00 AM • GlobeNewswire

Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight

The non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.

07/24/2025, 1:00 PM • GlobeNewswire

Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight

The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.

07/14/2025, 1:00 PM • GlobeNewswire